Literature DB >> 3158318

Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes.

M L Dubocovich, N R Zahniser.   

Abstract

Binding of the radiolabeled antidepressant [3H]nomifensine to rat and rabbit striatal membranes has been characterized. The specific binding of [3H]nomifensine to striatal membranes was stable, reversible and saturable. Saturation experiments indicated that [3H]nomifensine labeled a single site with an affinity (Kd) of 80 nM and a total number of binding sites (Bmax) of 6.5 pmoles/mg protein both in rat and rabbit striatal membranes. The affinity constants obtained from kinetic analyses and competition experiments were in fairly good agreement with those obtained in saturation experiments. Compounds known to inhibit [3H]dopamine uptake in vitro, such as nomifensine, 4-hydroxy-nomifensine, mazindol, amfonelic acid and benztropine, were the most potent competitors of nomifensine binding. Additionally, the absolute potencies of various drugs in competing for [3H]nomifensine binding to rat and rabbit striatal membranes correlated closely with their potencies in inhibiting [3H]dopamine uptake into striatal synaptosomes. Specific [3H]nomifensine binding was dependent on the presence of NaCl which is also consistent with its association with the dopamine uptake pump. The number, but not the affinity, of striatal [3H]nomifensine binding sites was reduced significantly following in vivo lesions with 6-hydroxydopamine. The number of [3H]nomifensine binding sites was found to be highest in areas rich in dopamine nerve terminals such as the striatum and olfactory tubercle. These results suggest that [3H]nomifensine binds to a site on dopaminergic nerve terminals associated with the dopamine uptake pump.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158318     DOI: 10.1016/0006-2952(85)90486-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

2.  Characterization of the human dopamine transporter heterologously expressed in BHK-21 cells.

Authors:  T Lenhard; K Marheineke; B Lingen; W Haase; R Hammermann; H Michel; H Reiländer
Journal:  Cell Mol Neurobiol       Date:  1998-06       Impact factor: 5.046

3.  Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935.

Authors:  M E Reith; G Selmeci
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

4.  Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.

Authors:  C M Dersch; H C Akunne; J S Partilla; G U Char; B R de Costa; K C Rice; F I Carroll; R B Rothman
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

5.  Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices.

Authors:  J Fang; P H Yu
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

6.  Facilitating effect of amphetamine on the response of rabbit aortic strips to adrenaline, dopamine and serotonin.

Authors:  B Silvestrini; M Palmery; F Basta; P Valeri
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  Characterization of the effects of serotonin on the release of [3H]dopamine from rat nucleus accumbens and striatal slices.

Authors:  B Nurse; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1988-05       Impact factor: 3.996

8.  Spermine interacts with cocaine binding sites on dopamine transporters.

Authors:  M C Ritz; C R Mantione; E D London
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

9.  Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.

Authors:  T B Mulder; J B de Vries; D Dijkstra; J W Wiechers; C J Grol; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

10.  DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum.

Authors:  L P Dwoskin; A L Jewell; L A Cassis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.